Discovery of Thiazolidine-2,4-Dione/Biphenylcarbonitrile Hybrid as Dual PPAR α/γ Modulator with Antidiabetic Effect: In vitro, In Silico and In Vivo Approaches

Chemical Biology and Drug Design

Volumn 81, Issue 4, 2013, Pages 474-483

  Hidalgo Figueroa, Sergio ^a   Ramírez Espinosa, Juan J ^a   Estrada Soto, Samuel ^a   Almanza Pérez, Julio C ^b   Román Ramos, Rubén ^b   Alarcón Aguilar, Francisco J ^b   Hernández Rosado, Jesús V ^b   Moreno Díaz, Hermenegilda ^c   Díaz Coutiño, Daniel ^c   Navarrete Vázquez, Gabriel ^a  

^a UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MORELOS   (Mexico)

^b DEPARTAMENTO DE QUÍMICA   (Mexico)

^c UNIVERSIDAD DEL PAPALOAPAN   (Mexico)

Author keywords

2,4 thiazolidinedione; Diabetes; Dual agonist; Hydrogen bonds; Molecular docking; PPAR

Indexed keywords

4'[[4 [(2,4 DIOXO 1,3MTHIAZOLIDIN 5 YLIDENE)METHYL]PHENOXY]METHYL]1,1' BIPHENYL 2 CARBONITRILE; 4[[4 [(2,4,6 TRIOXOTETRAHYDROPYRIMIDIN 5(2H) YLIDENE)METHYL]PHENOXY]METHYL]BIPHENYL 2 CARBONITRILE; ANTIDIABETIC AGENT; BARBITURIC ACID DERIVATIVE; CYANIDE; ETHYL [4 [(2,4 DIOXO 1,3 THIAZOLIDIN 5 YLIDENE)METHYL]PHENOXY]ACETATE; ETHYL [4 [(2,4,6 TRIOXOTETRAHYDROPYRIMIDIN 5(2H) YLIDENE)METHYL]PHENOXY]ACETATE; GLUCOSE TRANSPORTER 4; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; THIAZOLIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; COMPUTER MODEL; CONTROLLED STUDY; DISEASE MODEL; ENZYME ACTIVE SITE; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MALE; MASS SPECTROMETRY; MOLECULAR DOCKING; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; SINGLE DRUG DOSE;

3T3-L1 CELLS; ANIMALS; BARBITURATES; BINDING SITES; BLOOD GLUCOSE; CATALYTIC DOMAIN; DIABETES MELLITUS, EXPERIMENTAL; DRUG EVALUATION, PRECLINICAL; GLUCOSE TRANSPORTER TYPE 4; HUMANS; HYDROGEN BONDING; HYPOGLYCEMIC AGENTS; MALE; MICE; MOLECULAR DOCKING SIMULATION; NITRILES; PPAR ALPHA; PPAR GAMMA; RATS; RATS, WISTAR; RNA, MESSENGER; THIAZOLIDINEDIONES; THIAZOLIDINES; TRANSCRIPTION, GENETIC;

RATTUS;

EID: 84875679027     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12102     Document Type: Article

References (22)

1. Lee C.H., Olson P., Evans R.M. (2003) Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology;144:2201-2207.
2. Willson T.M., Brown P.J., Sternbach D.D., Henke B.R. (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem;43:527-550.
3. Sharma A.K., Sk U.H., He P., Peters J.M., Amin S. (2010) Synthesis of isosteric selenium analog of the PPARbeta/delta agonist GW501516 and comparison of biological activity. Bioorg Med Chem Lett;20:4050-4052.
4. Wild S., Roglic G., Green A., Sicree R., King H. (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care;27:1047-1053.
5. Navarrete-Vazquez G., Ramírez-Martínez M., Estrada-Soto S., Nava-Zuazo C., Paoli P., Camici G., Escalante-García J., Medina-Franco J.L., López-Vallejo F., Ortiz-Andrade R. (2012) Synthesis, in vitro and in silico screening of ethyl 2-(6-substituted benzo[d]thiazol-2-ylamino)-2-oxoacetates as protein-tyrosine phosphatase 1B inhibitors. Eur J Med Chem;53:346-355.
6. Balakumar P., Rose M., Ganti S.S., Krishan P., Singh M. (2007) PPAR dual agonists: are they opening Pandora's Box? Pharmacol Res;56:91-98.
7. Adeghate E., Adem A., Hasan M.Y., Tekes K., Kalasz H. (2011) Medicinal chemistry and actions of dual and pan PPAR modulators. Open Med Chem J;5(Suppl. 2):93-98.
8. Cox S.L. (2006) Tesaglitazar: a promising approach in type 2 diabetes. Drugs Today (Barc);42:139-146.
9. Sundriyal S., Viswanad B., Ramarao P., Chakraborti A.K., Bharatam P.V. (2008) New PPARgamma ligands based on barbituric acid: virtual screening, synthesis and receptor binding studies. Bioorg Med Chem Lett;18:4959-4962.
10. Momose Y., Maekawa T., Yamano T., Kawada M., Odaka H., Ikeda H., Sohda T. (2002) Novel 5-substituted 2, 4-thiazolidinedione and 2, 4-oxazolidinedione derivatives as insulin sensitizers with antidiabetic activities. J Med Chem;45:1518-1534.
11. Momose Y., Maekawa T., Odaka H., Ikeda H., Sohda T. (2002) Novel 5-substituted-1H-tetrazole derivatives as potent glucose and lipid lowering agents. Chem Pharm Bull;50:100-111.
12. Garcia-Macedo R., Sanchez-Muñoz F., Almanza-Perez J.C., Duran-Reyes G., Alarcon-Aguilar F., Cruz M. (2008) Glycine increases mRNA adiponectin and diminishes pro-inflammatory adipokines expression in 3T3-L1 cells. Eur J Pharmacol;587:317-321.
13. Almanza-Perez J.C., Alarcon-Aguilar F.J., Blancas-Flores G., Campos-Sepulveda A.E., Roman-Ramos R., Garcia-Macedo R., Cruz M. (2010) Glycine regulates inflammatory markers modifying the energetic balance through PPAR and UCP-2. Biomed Pharmacother;64:534-540.
14. Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J. (2009) Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem;16:2785-2791.
15. Torres-Piedra M., Ortiz-Andrade R., Villalobos-Molina R., Singh N., Medina-Franco J.L., Webster S.P., Binnie M., Navarrete-Vázquez G., Estrada-Soto S. (2010) A comparative study of flavonoid analogues on streptozotocin-nicotinamide induced diabetic rats: quercetin as a potential antidiabetic agent acting via 11β-hydroxysteroid dehydrogenase type 1 inhibition. Eur J Med Chem;45:2606-2612.
16. Nevin D.K., Lloyd D.G., Fayne D. (2011) Rational targeting of peroxisome proliferating activated receptor subtypes. Curr Med Chem;18:5598-5623.
17. Tsao T.S., Li J., Chang K.S., Stenbit A.E., Galuska D., Anderson J.E., Zierath J.R., McCarter R.J., Charron M.J. (2001) Metabolic adaptations in skeletal muscle overexpressing GLUT4: effects on muscle and physical activity. FASEB J;15:958-969.
18. Zisman A., Peroni O.D., Abel E.D., Michael M.D., Mauvais-Jarvis F., Lowell B.B., Wojtaszewski J.F., Hirshman M.F., Virkamaki A., Goodyear L.J., Kahn C.R., Kahn B.B. (2000) Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat Med;6:924-928.
19. Méndez-Lucio O., Pérez-Villanueva J., Castillo R., Medina-Franco J.L. (2012) Activity landscape modeling of PPAR ligands with dual-activity difference maps. Bioorg Med Chem;20:3523-3532.
20. Xu L., Chen Y., Pan Y., Skiles G.L., Shou M. (2009) Prediction of human drug-drug interactions from time-dependent inactivation of CYP3A4 in primary hepatocytes using a population-based simulator. Drug Metab Dispos;37:2330-2339.
21. Taboureau O., Jørgensen F.S. (2011) In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology. Comb Chem High Throughput Screen;14:375-387.
22. Moreno-Díaz H., Villalobos-Molina R., Ortiz-Andrade R., Díaz-Coutiño D., Medina-Franco J.L., Webster S.P., Binnie M., Estrada-Soto S., Ibarra-Barajas M., León-Rivera I., Navarrete-Vázquez G. (2008) Antidiabetic activity of N-(6-substituted-1, 3-benzothiazol-2-yl)benzenesulfonamides. Bioorg Med Chem Lett;18:2871-2877.